AnaptysBio Inc Stock
Price
Target price
€24.00
€24.00
0.840%
0.2
0.840%
€45.21
09.05.24 / Frankfurt
WKN: A2AJ8C / Symbol: ANAB / Name: AnaptysBio / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
AnaptysBio Inc Stock
AnaptysBio Inc gained 0.840% compared to yesterday.
We see a rather positive sentiment for AnaptysBio Inc with 9 Buy predictions and 1 Sell predictions.
With a target price of 45 € there is a hugely positive potential of 87.5% for AnaptysBio Inc compared to the current price of 24.0 €.
Pros and Cons of AnaptysBio Inc in the next few years
Pros
?
G***** c******* t* c**********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Cons
?
B****
?
S********** s********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of AnaptysBio Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| AnaptysBio Inc | 0.840% | -2.439% | 16.505% | 23.077% | 23.711% | 13.208% | - |
| Immunic Inc. | -3.200% | -4.224% | -8.249% | -27.890% | -17.552% | -89.073% | - |
| NanoViricides Inc. | 20.920% | 83.168% | 58.120% | 62.281% | 95.767% | -34.767% | -55.357% |
| Ocuphire Pharma Inc. | -10.910% | -7.977% | -7.334% | -71.922% | -43.041% | - | - |
Comments
AnaptysBio, Inc. (NASDAQ: ANAB) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $34.00 price target on the stock.
Show more
Ratings data for ANAB provided by MarketBeat
AnaptysBio, Inc. (NASDAQ: ANAB) is now covered by analysts at SVB Leerink LLC. They set an "outperform" rating and a $47.00 price target on the stock.
Show more
Ratings data for ANAB provided by MarketBeat
AnaptysBio, Inc. (NASDAQ: ANAB) was upgraded by analysts at Wedbush from a "neutral" rating to an "outperform" rating. They now have a $34.00 price target on the stock, up previously from $20.00.
Show more
Ratings data for ANAB provided by MarketBeat
News
Why AnaptysBio Stock Zoomed Nearly 8% Higher This Week
Many stocks were wobbly over the past few trading days, but we can't say that about biotech AnaptysBio (NASDAQ: ANAB). The company's shares closed the week almost 8% higher in price, according to
